Catalyst Pharmaceuticals, Inc.
CPRX
$21.81
$0.793.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 141.82M | 128.70M | 122.71M | 98.51M | 110.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.82M | 128.70M | 122.71M | 98.51M | 110.57M |
| Cost of Revenue | 14.57M | 22.56M | 18.39M | 15.10M | -73.89M |
| Gross Profit | 127.25M | 106.13M | 104.32M | 83.41M | 184.46M |
| SG&A Expenses | 44.19M | 45.88M | 40.73M | 46.94M | 42.04M |
| Depreciation & Amortization | 9.34M | 9.35M | 9.34M | 9.34M | 9.06M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.98M | 77.79M | 68.46M | 71.38M | 68.88M |
| Operating Income | 62.84M | 50.91M | 54.25M | 27.13M | 41.69M |
| Income Before Tax | 74.18M | 57.21M | 55.79M | 29.09M | 46.71M |
| Income Tax Expenses | 18.25M | 13.32M | 14.99M | 5.81M | 11.86M |
| Earnings from Continuing Operations | 55.94M | 43.88M | 40.79M | 23.28M | 34.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.94M | 43.88M | 40.79M | 23.28M | 34.84M |
| EBIT | 62.84M | 50.91M | 54.25M | 27.13M | 41.69M |
| EBITDA | 72.30M | 60.36M | 63.68M | 36.56M | 50.84M |
| EPS Basic | 0.47 | 0.37 | 0.35 | 0.20 | 0.33 |
| Normalized Basic EPS | 0.35 | 0.29 | 0.31 | 0.16 | 0.25 |
| EPS Diluted | 0.44 | 0.35 | 0.33 | 0.19 | 0.31 |
| Normalized Diluted EPS | 0.33 | 0.28 | 0.29 | 0.15 | 0.24 |
| Average Basic Shares Outstanding | 119.89M | 118.93M | 118.18M | 116.81M | 106.71M |
| Average Diluted Shares Outstanding | 126.28M | 125.41M | 124.66M | 123.40M | 113.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
